Study on chromosomal rearrangements in yeast reveals potential avenue for cancer therapy
(Osaka University) Researchers from Osaka University have found that the attachment of a ubiquitin molecule to a protein called PCNA at the lysine 107 position causes gross chromosomal rearrangements. This lysine is located where two PCNA molecules interact, and the ubiquitin attachment to it may change the ring structure they form. The ubiquitin attachment occurs through the action of Rad8 (a ubiquitin ligase) and Mms2-Ubc4 (a ubiquitin conjugating enzyme). This implies that inhibiting the human equivalent of this ubiquitination could prevent cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Cancer: Information theory to fight resistance to treatments
(Universit é de Gen è ve) A major challenge in cancer therapy is the adaptive response of cancer cells to targeted therapies. Although this adaptive response is theoretically reversible, such a reversal is hampered by numerous molecular mechanisms that allow the cancer cells to adapt to the treatment. A team (UNIGE/HUG) has used information theory, in order to objectify in vivo the molecular regulations at play in the mechanisms of the adaptive response and their modulation by a therapeutic combination. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 21, 2021 Category: International Medicine & Public Health Source Type: news

Scientists provide new insight on how to stop transcription of cancer cells
(University of California - Los Angeles Health Sciences) Findings could help pave the way for cancer therapies that target TAF12, potentially stopping transcription in cancer cells and helping decrease the growth of cancerous tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Homing Technology Delivers Therapy to Cancerous Bone
A clever approach to modifying already existing cancer therapies may be a game changer for treating metastatic breast cancer. (Source: The Scientist)
Source: The Scientist - July 19, 2021 Category: Science Tags: Sponsored Article Source Type: news

Swiss Researchers Develop a Multi-omic Tumor Profiler to Inform Clinical Decision Support and Guide Precision Medicine Therapy for Cancer Patients
New biomarkers for cancer therapies derived from the research could usher in superior clinical laboratory diagnostics that identify a patient’s suitability for personalized drug therapies and treatments In another advancement toward accurate precision medicine, Swiss researchers from the University Hospitals of Zurich and Basel, ETH Zurich, the University of Zurich, and pharmaceutical company Roche have […] The post Swiss Researchers Develop a Multi-omic Tumor Profiler to Inform Clinical Decision Support and Guide Precision Medicine Therapy for Cancer Patients appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - July 19, 2021 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Digital Pathology International Laboratory News Laboratory Pathology Laboratory Testing Molecular Diagnostics, Genetic Testing, Whole Gene Sequencing Precision Medicine anatomic pathology Cancer Cell clinical laboratory clinical patholog Source Type: news

NSF grant to advance research in cancer treatment
(Virginia Tech) As a form of cancer therapy, histotripsy uses ultrasound imaging to monitor treatments in real-time, making it noninvasive with minimal side effects. Thus far, histotripsy has shown promising results in clinical studies for liver cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2021 Category: International Medicine & Public Health Source Type: news

Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples. (Source: The Scientist)
Source: The Scientist - July 16, 2021 Category: Science Tags: News & Opinion Source Type: news

Damon Runyon Cancer Research Foundation awards $4.8 million to rising investigators
(Damon Runyon Cancer Research Foundation) Damon Runyon Cancer Research Foundation has announced the 2021 recipients of the Damon Runyon Clinical Investigator award--six outstanding early career physician-scientists working to develop new cancer therapies under the mentorship of the nation's leading scientists and clinicians. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Antibiotic-Linked Antibody Attacks Cancer ’s Sinister Neighbor Cells
An unexpected and unprecedented finding may lead to improved cancer therapies. (Source: The Scientist)
Source: The Scientist - July 14, 2021 Category: Science Tags: Sponsored Article Source Type: news

PPIs Could Be Bad News for Oral Cancer Therapies PPIs Could Be Bad News for Oral Cancer Therapies
GIs may want to be mindful of prescribing PPIs for patients with cancer because they may adversely affect concomitant oral therapies.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 13, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Scientists discover nanoclusters effective for cancer in the second near-infrared synergy therapy
(Hefei Institutes of Physical Science, Chinese Academy of Sciences) As a minimally invasive method for cancer therapy at precise locations, NIR-induced photothermal therapy (PTT) has drawn extensively attention. The therapeutic mechanism is the use of photothermal agents (PTAs) in the treatment of tumors,and its therapeutic effect happens only at the tumor site where both light-absorbent and localized laser radiation coexist. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2021 Category: Cancer & Oncology Source Type: news

Tool helps predict who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 12, 2021 Category: Universities & Medical Training Source Type: news

Anti-tumor agent from the intestine
(University of W ü rzburg) Certain metabolites of bacteria from the intestine make immune cells more aggressive as a new study conducted by scientists from german universities in W ü rzburg and Marburg reveals. The findings could help improve cancer therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2021 Category: International Medicine & Public Health Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
A new prognostic tool developed by researchers from theUCLA Jonsson Comprehensive Cancer Center and five other institutionshelps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.The tool,described in a study published today in Lancet Oncology, analyzesa wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.LuPSMA, which binds to PSMA proteins and delivers targeted radiation to prostate cancer tissue, offers a new option to men with PSMA-positive...
Source: UCLA Newsroom: Health Sciences - July 9, 2021 Category: Universities & Medical Training Source Type: news

Tool helps predicts who will respond best to targeted prostate cancer therapy
(University of California - Los Angeles Health Sciences) A new prognostic tool helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

RaySearch brings RayStation 9 to China
Radiation therapy software developer RaySearch Laboratories has received regulator...Read more on AuntMinnie.comRelated Reading: RaySearch secures $2.2M Swiss contract RaySearch releases update of RayStation software RaySearch, TAE Life Sciences partner on cancer therapy AI algorithm boosts Swedish clinic's workflow RaySearch unveils new RayStation release (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2021 Category: Radiology Source Type: news

Cancer therapy: Integration of reactive oxygen species generation and prodrug activation
(Compuscript Ltd) https://doi.org/10.15212/bioi-2021-0011Announcing a new article publication for BIO Integration journal. In this article the authors Xiao'en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang from Tianjin University, Tianjin, China discuss the integration of reactive oxygen species generation and prodrug activation for cancer therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news

Reactive oxygen species (ROS): Key components in cancer therapies
(Bentham Science Publishers) This review highlights the genesis of ROS within cells by various routes and their role in cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 30, 2021 Category: Cancer & Oncology Source Type: news

Study sheds light on persistent racial disparities in prostate cancer care in the United States
(NYU Langone Health / NYU Grossman School of Medicine) Black men most likely to benefit from advanced prostate cancer therapies are 11% less likely to get them than non-Black men. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 29, 2021 Category: Cancer & Oncology Source Type: news

Moffitt receives $10.2 million grant to develop new lung cancer therapies
(H. Lee Moffitt Cancer Center& Research Institute) The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984). The grant, which will provide more than $10.2 million over five years, will support team research with a focus on investigating lung cancer metabolism. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

NYUAD study finds protein aggregation inhibitor can be used to develop cancer therapies
(New York University) A new study provides important insights into the p53 protein, a critical tumor suppressor often mutated and deactivated in cancer, and a key target in the development of cancer therapeutics. Using protein mimetics (small molecules that mimic proteins) originally designed to prevent aggregation of proteins associated with Alzheimer's disease and type II diabetes, the researchers were able to breakdown p53 aggregates and reactivate the protein, leading to the death of cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2021 Category: Cancer & Oncology Source Type: news

Makowski, Pierre publish findings on obesity and response to cancer therapy
(University of Tennessee Health Science Center) Liza Makowski, PhD, professor in the Department of Medicine and the UTHSC Center for Cancer Research, has long been interested in how the immune system is altered by obesity and how this impacts cancer risk and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2021 Category: International Medicine & Public Health Source Type: news

Georgia firm, UT Health SA to develop new cancer therapy and research center
The multistory facility will offer patients an alternative to conventional radiation treatment. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 24, 2021 Category: Pharmaceuticals Authors: W. Scott Bailey Source Type: news

RaySearch secures $2.2M Swiss contract
Radiation therapy software developer RaySearch Laboratories has secured a $2.2 millio...Read more on AuntMinnie.comRelated Reading: RaySearch releases update of RayStation software RaySearch's new planning system treats 1st patients in Japan Canon Medical, RaySearch expand partnership RaySearch, TAE Life Sciences partner on cancer therapy AI algorithm boosts Swedish clinic's workflow (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2021 Category: Radiology Source Type: news

Tmunity enacts layoffs after deaths of 2 patients halt study of experimental prostate cancer therapy
Tmunity is attempting to adapt CAR T-cell therapy, which has proven to be effective in certain blood cancers, for use in patients with solid tumors. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 18, 2021 Category: Biotechnology Authors: John George Source Type: news

Adding checkpoint inhibition to anti-HER2 breast cancer therapy brings no benefit
(European Society for Medical Oncology) Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary. The phase III trial is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody atezolizumab in patients with high-risk, HER2-positive early breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ludwig cancer research study shows how novel drug screen can individualize cancer therapy
(Ludwig Institute for Cancer Research) A study conducted by researchers at the Ludwig Center at Harvard has demonstrated how a drug screening method known as dynamic BH3 profiling can be used to quickly identify potentially effective combinations of existing drugs for personalized cancer therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2021 Category: International Medicine & Public Health Source Type: news

ONK Therapeutics and Trinity researchers seek improved cancer therapies
(Trinity College Dublin) ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has been awarded an Innovation Partnership Programme (IPP) grant by Enterprise Ireland (EI) to fund collaborative research at Trinity College Dublin, Ireland, led by Dr. David Finlay to optimize the metabolism and engineering of NK cells for improved cancer therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 8, 2021 Category: International Medicine & Public Health Source Type: news

Idiosyncratic Drug-Induced Liver Injury: New Guidelines Idiosyncratic Drug-Induced Liver Injury: New Guidelines
New guidelines offer recommendations on the management of idiosyncratic drug-induced liver injury, which is increasing, driven by the popularity of supplements and the use of some cancer therapies.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 8, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

NIH grant boosts computational search for cancer drugs
(Rice University) Rice computer scientist Lydia Kavraki won an NIH grant to create a data science-based proteomics toolkit to analyze protein-ligand interactions for new cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 7, 2021 Category: Cancer & Oncology Source Type: news

AI outperforms humans in creating cancer treatments, but do doctors trust it?
(University Health Network) The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 3, 2021 Category: Cancer & Oncology Source Type: news

Biotech firm Stellanova Therapeutics closes $15.5M Series A, names CEO
Houston-based biotechnology firm Stellanova Therapeutics raised $15.5 million to advance development of its cancer therapies. The Series A round was led by Houston-based Sporos Bioventures LLC, Stellanova announced June 3. Stellanova is developing therapies targeting the tumor microenvironment in order to treat cancers that are resistant to current therapies, the company said. Stellanova's lead clinical candidate is an antibody that targets DKK3, a factor promoting therapeutic resistance and… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 2, 2021 Category: Health Management Authors: Chris Mathews Source Type: news

Biotech firm Stellanova Therapeutics closes $15.5M Series A, names CEO
Houston-based biotechnology firm Stellanova Therapeutics raised $15.5 million to advance development of its cancer therapies. The Series A round was led by Houston-based Sporos Bioventures LLC, Stellanova announced June 3. Stellanova is developing therapies targeting the tumor microenvironment in order to treat cancers that are resistant to current therapies, the company said. Stellanova's lead clinical candidate is an antibody that targets DKK3, a factor promoting therapeutic resistance and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 2, 2021 Category: Biotechnology Authors: Chris Mathews Source Type: news

RaySearch releases update of RayStation software
Radiation therapy software developer RaySearch Laboratories has released 11A...Read more on AuntMinnie.comRelated Reading: RaySearch, TAE Life Sciences partner on cancer therapy RaySearch unveils new RayStation release RaySearch, Varian partner to track radiation therapy RaySearch inks Australian contract Accuray, RaySearch treat 1st patients in Asia-Pacific (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 2, 2021 Category: Radiology Source Type: news

BeyondSpring Announces U.S. FDA Acceptance And Priority Review Of New Drug Application For Plinabulin And G-CSF Combination For The Prevention Of Chemotherapy-Induced Neutropenia (CIN)
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE)— BeyondSpring Inc. (the“Company” or“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies,... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Circulogene receives patent approval for technology
A local molecular diagnostic company has received a patent for its proprietary cell-free nucleic acid (CfNA) preparation mythology.   Circulogene's patent covers methods for the amplification of cfNA, such as cell-free DNA, in a liquid sample. The patient describes how this mythology overcomes currently analysis limitations associated with large sample requirements. Circulogene’s technology serves as the foundation of the c ompany’s liquid biopsy workflow for targeted cancer therapy selection.… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 28, 2021 Category: American Health Authors: Tyler Patchen Source Type: news

Circulogene receives patent approval for technology
A local molecular diagnostic company has received a patent for its proprietary cell-free nucleic acid (CfNA) preparation mythology.   Circulogene's patent covers methods for the amplification of cfNA, such as cell-free DNA, in a liquid sample. The patient describes how this mythology overcomes currently analysis limitations associated with large sample requirements. Circulogene’s technology serves as the foundation of the c ompany’s liquid biopsy workflow for targeted cancer therapy selection.… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 28, 2021 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Clinician FAQs and guidance on covid-19 vaccine for patients receiving systemic anti-cancer therapy (SACT). version 4.0, UK Chemotherapy Board
This document has been revised to include updated information on the Pfizer/BioNTech COVID-19 vaccine, Oxford University/AstraZeneca vaccine and Moderna vaccine, reflecting updated guidance from JCVI and the MHRA. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 28, 2021 Category: Consumer Health News Source Type: news

Pioneering single-dose radiotherapy for breast cancer treatment
(University College London) A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional radiotherapy, and avoids potential damage to nearby organs. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 28, 2021 Category: International Medicine & Public Health Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cancer treatments may accelerate cellular aging
(Wiley) New research indicates that certain anti-cancer therapies may hasten cellular aging, where changes in the DNA of patients may contribute to greater inflammation and fatigue. The findings are published by Wiley early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Ludwig Cancer research study finds way to revive potent immune cells for cancer therapy
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Dental school researcher gets approval to begin clinical trials for cancer therapy
(Rutgers University) A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received US Food and Drug Administration (FDA) approval to treat cancer patients with a therapy based on Kachlany's discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2021 Category: Cancer & Oncology Source Type: news

Breast cancer treatments do not increase risk of Covid-19 infection or death
(NYU Langone Health / NYU Grossman School of Medicine) Cancer drugs capable of weakening the body's immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows. Researchers say the results challenge initial concerns that such treatments, which poison cancer cells, were too dangerous to continue during the pandemic. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 19, 2021 Category: Cancer & Oncology Source Type: news

New technology makes tumor eliminate itself
(University of Zurich) A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could reduce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2021 Category: Biology Source Type: news

Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 17, 2021 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

Heart-protecting drugs likely unnecessary for many breast cancer patients
(American College of Cardiology) Taking medications to protect the heart from damage associated with adjuvant breast cancer therapy--medications that are administered in addition to surgery to remove a tumor--did not significantly improve markers of heart health two years after breast cancer treatment, according to a study presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 16, 2021 Category: Cancer & Oncology Source Type: news

BioNTech powers to profit on Covid vaccine demand
German group plans to invest proceeds in bid to become a leading force in cancer therapies (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 10, 2021 Category: Pharmaceuticals Source Type: news

St. Louis-born Galera's stock soars after release of positive study data for its experimental cancer therapy
Galera Therapeutics' stock price jumped 41% Thursday morning after the St. Louis-born biopharmaceutical company provided updated results from early-stage testing of its experimental therapy for advanced pancreatic cancer. The company's stock began trading Thursday at $9.34 per share after closing Wednesday at $6.61. (Galera's stock simmered down later, closing Thursday at $8.12 a share and opening Friday morning at $7.89.) Galera (NASDAQ: GRTX) is developing proprietary therapies that have the… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 30, 2021 Category: Health Management Authors: John George Source Type: news